Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.41 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.41 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651759 | 0.99 | IGF2R (0.43) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL1134654 | 0.99 | IGF2R (0.43) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL114715 | 0.99 | IGF2R (0.43) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL8885773 | 0.97 | IGF2R (0.47) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL8884633 | 0.97 | IGF2R (0.47) | IGF2RLGALS8LGALS3LGALS4 | |
| Water SCHEMBL21777653 | 0.97 | IGF2R (0.42) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL8883154 | 0.95 | IGF2R (0.48) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL8884277 | 0.95 | IGF2R (0.48) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL346230 | 0.90 | IGF2R (0.43) | IGF2RLGALS8LGALS3LGALS4ITPR3 | |
| SCHEMBL8883415 | 0.90 | IGF2R (0.44) | IGF2RLGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108127-A1 | HYPOTONIC COMPOSITION FOR FAT DECOMPOSITION AND METHOD FOR PREPARING SAME | LEE KYOUNG LACK (KR) | 2020-04-09 | — | — | US | claimed |
| CN-102440956-B | Preparation method of self-emulsified sumatriptan and salt preparation thereof | UNIV PLA 3RD MILITARY MEDICAL | 2013-06-05 | — | — | CN | claimed |
| CN-102440956-A | Preparation method of self-emulsifying sumatriptan and salt preparation thereof | UNIV PLA 3RD MILITARY MEDICAL | 2012-05-09 | — | — | CN | claimed |
| CN-119060104-A | Method for obtaining high-purity lactose | 国药集团化学试剂有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118749028-A | Recombinant attenuated RSV live vaccine strain and method for producing the same | SK生物科学株式会社 | 2024-10-08 | — | — | CN | disclosed |
| EP-4410969-A1 | RECOMBINANT LIVE ATTENUATED RSV VACCINE STRAIN AND PRODUCTION METHOD THEREFOR | SK Bioscience Co., Ltd. (KR) | 2024-08-07 | — | — | EP | disclosed |
| EP-4352071-A1 | MACROLIDE COMPOUNDS | Vanderbilt University (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023212519-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230021481-A1 | STANDARD SUBSTANCE FOR PSA QUANTIFICATION, PREPARATION METHOD THEREFOR, STANDARD SOLUTION FOR PSA QUANTIFICATION, AND PSA QUANTIFICATION METHOD | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4079752-A1 | STANDARD SUBSTANCE FOR PSA QUANTIFICATION, PREPARATION METHOD THEREFOR, STANDARD SOLUTION FOR PSA QUANTIFICATION, AND PSA QUANTIFICATION METHOD | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022035248-A1 | VACCINE COMPOSITION FOR PREVENTING TUBERCULOSIS COMPRISING CHORISMATE MUTASE | 서울대학교산학협력단 | 2022-02-17 | — | — | WO | disclosed |
| WO-2002036756-A2 | LACTOBACILLUS STRAIN, AND PLASMID HOSTED BY SAME | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (FR) | 2002-05-10 | — | — | WO | disclosed |
| EP-1111390-A1 | METHOD FOR EVALUATING LIPID A ANALOG-CONTAINING INJECTIONS | Eisai Co., Ltd. (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-0805676-A1 | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SLOW RELEASE TABLETS BASED ON HIGH MOLECULAR WEIGHT POLYSACCHARIDE GRANULES | RHONE-POULENC CHIMIE (FR) | 1997-11-12 | — | — | EP | disclosed |
| EP-0514588-B1 | Novel phosphobetaine and detergent and cosmetic containing the same | KAO CORP (JP) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996022767-A1 | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SLOW RELEASE TABLETS BASED ON HIGH MOLECULAR WEIGHT POLYSACCHARIDE GRANULES | RHONE-POULENC CHIMIE (FR) | 1996-08-01 | — | — | WO | disclosed |
| US-5468286-A | Enzymatically debranched starches as tablet excipients | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 1995-11-21 | — | — | US | disclosed |
| US-5409705-A | Phosphobetaine and detergent and cosmetic containing the same | KAO CORPORATION (JP) | 1995-04-25 | — | — | US | disclosed |
| EP-0514588-A2 | Novel phosphobetaine and detergent and cosmetic containing the same | Kao Corporation (JP) | 1991-11-25 | — | — | EP | disclosed |
| US-4382967-A | MOISTENING WITH WATER; HEATING; CRYSTALLIZATION; ABSORPTION OF VEGETABLE OILS; CAKE AND SOUP MIXES; FREE-FLOWING | HOUSE FOOD INDUSTRIAL COMPANY LIMITED (JP) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021481-A1 | STANDARD SUBSTANCE FOR PSA QUANTIFICATION, PREPARATION METHOD THEREFOR, STANDARD SOLUTION FOR PSA QUANTIFICATION, AND PSA QUANTIFICATION METHOD | PSAT1, KLK3, PSAP | IGF2R 1551/4885LGALS8 178/4885LGALS3 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.